Bioflavonoid ellagic acid inhibits aldose reductase: Implications for prevention of diabetic complications

Journal of Functional Foods

Volumn 6, Issue 1, 2014, Pages 374-383

  Akileshwari, Chandrasekhar ^a   Raghu, Ganugula ^a   Muthenna, Puppala ^a   Mueller, Niklaus H ^b   Suryanaryana, Palla ^a   Petrash, J Mark ^b   Reddy, G Bhanuprakash ^a  

^a NATIONAL INSTITUTE OF NUTRITION   (India)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Aldehyde reductase; Aldose reductase; Diabetic cataract; Ellagic acid; Lens opacity; Sorbitol

Indexed keywords

EID: 84895069853     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2013.11.004     Document Type: Article

References (37)

1. Akileshwari C., Muthenna P., Nastasijevic B., Joksic G., Petrash J.M., Reddy G.B. Inhibition of aldose reductase by Gentiana lutea extracts. Experimental Diabetes Research 2012, 2012:147965.
2. Ballali S., Lanciai F. Functional food and diabetes: A natural way in diabetes prevention?. International Journal of Food Sciences and Nutrition 2012, 63(Suppl. 1):51-61.
3. Bhatnagar A., Srivastava S.K. Aldose reductase: Congenial and injurious profiles of an enigmatic enzyme. Biochemical Medicine and Metabolic Biology 1992, 48(2):91-121.
4. Bohren K.M., Grimshaw C.E. The sorbinil trap: A predicted dead-end complex confirms the mechanism of aldose reductase inhibition. Biochemistry 2000, 39(32):9967-9974.
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414(6865):813-820.
6. Corbett S., Daniel J., Drayton R., Field M., Steinhardt R., Garrett N. Evaluation of the anti-inflammatory effects of ellagic acid. Journal of Perianesthesia Nursing 2010, 25(4):214-220.
7. Diabetes Atlas, 5th edition. (2011). Internal Diabetes Federation.
8. Foppiano M., Lombardo G. Worldwide pharmacovigilance systems and tolrestat withdrawal. The Lancet 1997, 349(9049):399-400.
9. Heber D. Multitargeted therapy of cancer by ellagitannins. Cancer Letters 2008, 269(2):262-268.
10. Jurenka J.S. Therapeutic applications of pomegranate (Punica granatum L.): A review. Alternative Medicine Review 2008, 13(2):128-144.
11. Kador P.F., Kinoshita J.H., Sharpless N.E. Aldose reductase inhibitors: A potential new class of agents for the pharmacological control of certain diabetic complications. Journal of Medicinal Chemistry 1985, 28(7):841-849.
12. Kinoshita J.H. A thirty year journey in the polyol pathway. Experimental Eye Research 1990, 50(6):567-573.
13. Klebe G., Kramer O., Sotriffer C. Strategies for the design of inhibitors of aldose reductase, an enzyme showing pronounced induced-fit adaptations. Cellular and Molecular Life Sciences 2004, 61(7-8):783-793.
14. Lee W.J., Ou H.C., Hsu W.C., Chou M.M., Tseng J.J., Hsu S.L., Tsai K.L., Sheu W.H. Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells. Journal of Vascular Surgery 2010, 52(5):1290-1300.
15. Matsuda H., Morikawa T., Toguchida I., Yoshikawa M. Structural requirements of flavonoids and related compounds for aldose reductase inhibitory activity. Chemical & Pharmaceutical Bulletin (Tokyo) 2002, 50(6):788-795.
16. Michael J., Fowler M.D. Microvascular and macrovascular complications of diabetes. Clinical Diabetes 2008, 26(2):77-82.
17. Muthenna P., Akileshwari C., Reddy G.B. Ellagic acid, a new antiglycating agent: Its inhibition of N-(carboxymethyl)lysine. Biochemical Journal 2012, 442(1):221-230.
18. Muthenna P., Suryanarayana P., Gunda S.K., Petrash J.M., Reddy G.B. Inhibition of aldose reductase by dietary antioxidant curcumin: Mechanism of inhibition, specificity and significance. FEBS Letters 2009, 583(22):3637-3642.
19. Petrash J.M., Harter T.M., Devine C.S., Olins P.O., Bhatnagar A., Liu S., Srivastava S.K. Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80, -298 and -303. Journal of Biological Chemistry 1992, 267(34):24833-24840.
20. Pfeifer M.A., Schumer M.P., Gelber D.A. Aldose reductase inhibitors: The end of an era or the need for different trial designs?. Diabetes 1997, 46(Suppl. 2):S82-89.
21. Rani P.U., Kesavan R., Ganugula R., Avaneesh T., Kumar P.U., Reddy G.B., Dixit M. Ellagic acid inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and prevents atheroma formation in streptozotocin-induced diabetic rats. Journal of Nutritional Biochemistry 2013, 24(11):1830-1839.
22. Raskin P., Rosenstock J. Aldose reductase inhibitors and diabetic complications. American Journal of Medicine 1987, 83(2):298-306.
23. Reddy P.Y., Giridharan N.V., Reddy G.B. Activation of sorbitol pathway in metabolic syndrome and increased susceptibility to cataract in Wistar-Obese rats. Molecular Vision 2012, 18:495-503.
24. Reddy G.B., Muthenna P., Akileshwari C., Saraswat M., Petrash J.M. Inhibition of aldose reductase and sorbitol accumulation by dietary rutin. Current Science 2011, 101(9):1191-1197.
25. Reddy G.B., Satyanarayana A., Balakrishna N., Ayyagari R., Padma M., Viswanath K., Petrash J.M. Erythrocyte aldose reductase activity and sorbitol levels in diabetic retinopathy. Molecular Vision 2008, 14:593-601.
26. Saraswat M., Muthenna P., Suryanarayana P., Petrash J.M., Reddy G.B. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pacific Journal of Clinical Nutrition 2008, 17(4):558-565.
27. Saraswat M., Reddy P.Y., Muthenna P., Reddy G.B. Prevention of non-enzymic glycation of proteins by dietary agents: Prospects for alleviating diabetic complications. Bristish Journal of Nutrition 2009, 101(11):1714-1721.
28. Saraswat M., Suryanarayana P., Reddy P.Y., Patil M.A., Balakrishna N., Reddy G.B. Antiglycating potential of Zingiber officinalis and delay of diabetic cataract in rats. Molecular Vision 2010, 16:1525-1537.
29. Shahidi F., Chandrasekara A. Millet grain phenolics and their role in disease risk reduction and health promotion: A review. Journal of Functional Foods 2013, 5(2):570-581.
30. Spite M., Baba S.P., Ahmed Y., Barski O.A., Nijhawan K., Petrash J.M., Bhatnagar A., Srivastava S. Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochemical Journal 2007, 405(1):95-105.
31. Srivastava S.K., Petrash J.M., Sadana I.J., Ansari N.H., Partridge C.A. Susceptibility of aldehyde and aldose reductases of human tissues to aldose reductase inhibitors. Current Eye Research 1982, 2(6):407-410.
32. Suryanarayana P., Kumar P.A., Saraswat M., Petrash J.M., Reddy G.B. Inhibition of aldose reductase by tannoid principles of Emblica officinalis: Implications for the prevention of sugar cataract. Molecular Vision 2004, 10:148-154.
33. Suryanarayana P., Saraswat M., Mrudula T., Krishna T.P., Krishnaswamy K., Reddy G.B. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. Investigative Ophthalmology & Visual Sciences 2005, 46(6):2092-2099.
34. Suryanarayana P., Saraswat M., Petrash J.M., Reddy G.B. Emblica officinalis and its enriched tannoids delay streptozotocin-induced diabetic cataract in rats. Molecular Vision 2007, 13:1291-1297.
35. Urzhumtsev A., Tete-Favier F., Mitschler A., Barbanton J., Barth P., Urzhumtseva L., Biellmann J.F., Podjarny A., Moras D. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil. Structure 1997, 5(5):601-612.
36. Varma S.D., Mikuni I., Kinoshita J.H. Flavonoids as inhibitors of lens aldose reductase. Science 1975, 188(4194):1215-1216.
37. Wu D., Ma X., Tian W. Pomegranate husk extract, punicalagin and ellagic acid inhibit fatty acid synthase and adipogenesis of 3T3-L1 adipocyte. Journal of Functional Foods 2013, 5(2):633-641.